Skip to main content

IN8BIO, INC.

For the period ended Jun 30, 2025. Filed Aug 7, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 7, 2025

INAB$0.93+11.6%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Balance Sheets

(In thousands, except share and per share data)

June 30,
2025December 31,
(unaudited)2024
Assets · (Note 2)
Current assets
Cash$13,226$11,120
Prepaid expenses and other current assets5151,458
Total Current Assets13,74112,578
Non-current assets
Property and equipment, net2,3472,858
Restricted cash271266
Right-of-use assets - finance leases5421,068
Right-of-use assets - operating leases2,1953,899
Other non-current assets275275
Total Non-Current Assets5,6308,366
Total Assets$19,371$20,944
Liabilities and Stockholders' Equity
Liabilities
Current liabilities
Accounts payable$379$389
Accrued expenses and other current liabilities6351,047
Short-term finance lease liability404694
Short-term operating lease liability536953
Total Current Liabilities1,9543,083
Long-term finance lease liability126295
Long-term operating lease liability2,0523,088
Total Non-Current Liabilities2,1783,383
Total Liabilities4,1326,466
Stockholders' Equity
Preferred stock, par value $0.0001 per share; 10,000,000 shares authorized at June 30, 2025 and December 31, 2024, respectively; no shares issued and outstanding——
Common stock, par value $0.0001 per share; 490,000,000 shares authorized at June 30, 2025 and December 31, 2024; 4,078,139 and 2,416,066 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively(1)107
Additional paid-in capital147,529136,127
Accumulated deficit(132,300)(121,656)
Total Stockholders' Equity15,23914,478
Total Liabilities and Stockholders' Equity$19,371$20,944

(1) All share amounts and per share amounts disclosed in this Quarterly Report on Form 10-Q have been restated to reflect a one-for-thirty reverse stock split effected in June 2025. See Note 1, Organization and Nature of Operations, for details.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.